{'fraction_non_alphanumeric': 0.03075030750307503, 'fraction_numerical': 0.00984009840098401, 'mean_word_length': 5.166666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.


 The Food and Drug Administration (FDA) has approved amprenavir (Agenerase, formerly known as 141W94 and VX-478) for treatment of HIV. The drug is a second-generation protease inhibitor, discovered by Vertex Pharmaceuticals and marketed by Glaxo Wellcome. The amprenavir regimen consists of eight capsules twice daily, with or without food. There is also a liquid formulation for pediatric use. Clinical studies show amprenavir to be a potent HIV inhibitor, that can penetrate the blood-brain barrier. Persons taking hormonal contraceptives or rifabutin will need to adjust the dose, while persons with sulfa allergies may have difficulty taking the drug. Several drugs including Astemizole (Hismanal) cannot be taken with amprenavir.
